-
Shionogi & Co., Ltd. Selected for METI’s FY2024 Supplementary Budget Grant Program for Future-Oriented Co-Creation with the Global South — Feasibility Study on the Use of Digital Solutions to Promote Appropriate Use of Japan-Origin Antimicrobials and Hygiene Products in Kenyan Healthcare Facilities
-
Submission of Letter of Intent and Concept Note to the Kenyan Ministry of Health to Accelerate Access to Cefiderocol
-
Shionogi, Nagasaki University, Saraya and Connect Afya Enter into a Comprehensive Partnership Agreement to Support Antimicrobial Stewardship in Kenya
-
ESCMID Global 2025: Shionogi Presents Real-World Data Demonstrating Better Clinical Outcomes When Fetcroja® / Fetroja® (Cefiderocol) Is Used as Empiric or Documented Therapy as Compared To Salvage Therapy for the Treatment of Gram-Negative Bacterial Infections
-
Exclusive Licensing Agreement with Link Healthcare, a Clinigen Company for Cefiderocol in Australia and New Zealand
-
Conclusion of a Comprehensive Collaboration Agreement with Osaka Metropolitan University in the Field of Infectious Diseases — Aiming to Establish the ‘Osaka Model’ for a City Resilient to Infectious Diseases through Industry-Government-Academia Collaboration
-
Approval for “Fetroja®”(cefiderocol) in South Korea
-
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
-
Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10M Award by BARDA as Part of Qpex’s Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections
-
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.